[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-diseases":757},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,51,0,25,[9,49,129,153,182,214,244,275,298,330,359,380,406,426,454,506,526,556,574,604,634,658,692,714,736],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100468924",false,"NCT05386108","Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+\u002FHER-2- Breast Cancer","An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination With Abemaciclib in Women and Men With Brain Metastasis From Estrogen Receptor Positive, HER-2 Negative Breast Cancer","ELECTRA","Inclusion Criteria:\n\n1. Participant has the signed informed consent form before any study-related activities according to local guidelines.\n2. Women or men aged ≥18 years, at the time of informed consent signature.\n\n   * Female participants may be either postmenopausal or pre\u002Fperimenopausal. Postmenopausal status is defined by:\n\n     1. Age ≥60 years\n     2. Age \\\u003C60 years and amenorrhea for 12 or more months without an alternative cause) and follicle stimulating hormone and estradiol in postmenopausal ranges per local reference ranges\n     3. Documentation of prior bilateral oophorectomy, at least 1 month before first dose of trial therapy).\n   * Pre-menopausal \u002F peri-menopausal women and men must be concurrently receiving a luteinizing hormone-releasing hormone (LHRH) agonist starting at least 3-4 weeks before the start of trial therapy and is planning to continue LHRH during the study.\n3. Participant must have ER-positive, HER-2 negative tumor status as confirmed by local laboratory testing in the following manner:\n\n   * Documentation of ER positive tumor with ≥ 1% staining by immunohistochemistry (IHC) as defined in the 2010 or 2020 American Society for Clinical Oncology (ASCO) recommendations for ER testing, with or without progesterone receptor (PGR) positivity\n   * HER-2 negative tumor with an IHC result of 0 or 1+ for cellular membrane protein expression or an in situ hybridization negative result as defined in the 2013 or 2018 ASCO recommendations for HER-2 testing\n4. In Phase 2, participants must have at least one active and measurable brain metastasis per RECIST version 1.1.\n\n   * Any of the following qualifies brain metastases as active:\n\n     1. Newly diagnosed brain metastasis in participants who never received prior central nervous system (CNS)-directed therapy.\n     2. Newly diagnosed brain metastasis outside any area that was previously subjected to CNS-directed therapy.\n     3. Brain metastases demonstrating unequivocal progression in the opinion of the treating investigator in an area that has previously been subjected to CNS-directed therapy.\n   * For lesions, including brain metastases, to qualify as measurable, and possibly be selected as target lesions, per RECIST version 1.1, the longest diameter must be ≥10 millimeters \\[mm\\] by computed tomography \\[CT\\] or magnetic resonance imaging \\[MRI\\]).\n   * In Phase 1b, the presence of brain metastases is allowed but not required for eligibility, in this case, at least 1 measurable lesion outside the brain is required.\n5. Participants receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 7 days prior to baseline and not receiving doses higher than 4 mg of dexamethasone per day or equivalent.\n6. Participants have experienced no more than one seizure within 4 weeks prior to starting trial therapy.\n7. Participants' prior therapy received in the metastatic setting includes:\n\n   * At least one endocrine therapy\n   * Up to two chemotherapy regimens\n   * Up to two lines of prior cyclin-dependent kinase (CDK) 4\u002F6 inhibitor, not including abemaciclib\n\n   Note 1: Toxicity from prior therapy must be resolved to NCI CTCAE version 5.0 Grade ≤1, with the exception of alopecia and peripheral sensory neuropathy (Grade ≤2).\n\n   Note 2: Chemotherapy refers to not targeted cytotoxic agents (for example, alkylating agents, taxanes, nucleotide analogs, platinum-based drugs, vinca alkaloids, etc) and antibody drug conjugates (ADCs). Targeted therapies (for example, kinase inhibitors) are not considered chemotherapy for eligibility purposes. Not targeted cytotoxic agents administered for less than 1 cycle will not be counted as a prior chemotherapy regimen.\n8. Participant has documented intracranial and\u002For extracranial radiological progression or recurrence while on or after the most recent therapy.\n9. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2\n10. Participant has a life expectancy ≥ 12 weeks.\n11. Participant has adequate bone marrow and organ function, as defined by the following laboratory values:\n\n    1. Absolute neutrophil count (ANC) ≥1.5 × 10\\^9\u002Fliter (L)\n    2. Platelets ≥100 × 10\\^9\u002FL\n    3. Hemoglobin ≥9.0 grams (g)\u002Fdeciliter (dL)\n    4. Potassium, sodium, calcium (corrected for serum albumin) and magnesium CTCAE Grade ≤1 (if screening assessments are abnormal, these assessments may be repeated up to 2 times; participants may receive appropriate supplementation or treatment prior to reassessment)\n    5. Creatinine clearance (per Cockcroft-Gault formula) ≥50 mL\u002Fminute\n    6. Serum albumin ≥3.0 g\u002FdL (≥30 g\u002FL)\n    7. Liver function tests:\n\n       In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × upper limit of normal (ULN). If the participant has liver metastases, ALT and AST ≤5.0 × ULN.\n    8. Total serum bilirubin \\\u003C1.5 × ULN except for participants with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤ 1.5 × ULN\n12. The participant is willing and able to adhere to the study visit schedule and other protocol requirements.\n\nExclusion Criteria:\n\n1. Immediate CNS-specific treatment is likely to be required, per the treating physician's assessment.\n2. Participant has imminent organ failure and\u002For visceral crisis.\n3. Participant has leptomeningeal metastases, defined as having positive cerebrospinal fluid (CSF) cytology or unequivocal radiologic and clinical evidence of leptomeningeal involvement. Note: Discrete dural metastases are permitted.\n4. Breast cancer treatment-naïve participants (that is, not having received any systemic therapy) in the advanced\u002Fmetastatic setting.\n5. History of pulmonary embolism (PE), cardiovascular accident (CVA), myocardial infarction (MI) in the past 6 months from screening visit.\n6. Prior therapy with abemaciclib in the metastatic setting. Note: Use of abemaciclib in the adjuvant setting is allowed if the last treatment administration was more than 12 months prior to first recurrence.\n7. Prior therapy with elacestrant or other investigational selective estrogen receptor degraders (SERDs), or investigational alike agents such as selective estrogen receptor modulators (SERMs), selective estrogen receptor covalent antagonists (SERCANs), complete estrogen receptor antagonists (CERANs), and proteolysistargeting chimeras (PROTACs) in the metastatic setting.\n8. Participant has a concurrent malignancy or malignancy within 3 years of enrollment, with the exception of adequately treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or second primary breast cancer; and any other malignancy that is considered in complete remission by the Investigator(s) that is approved by the Medical Monitor.\n9. Currently participating in another breast cancer intervention clinical study. Participants who are being followed for overall survival for another clinical trial with no therapy and study intervention are allowed after the washout period for any prior therapy.\n10. Prior anti-cancer or investigational drug treatment within the following windows:\n\n    * Fulvestrant treatment (last injection) \\\u003C42 days before first dose of study drug\n    * Any other endocrine therapy \\\u003C14 days before first dose of study drug. Note: LHRH agonists should not be counted as endocrine therapy.\n    * Chemotherapy or other anti-cancer therapy \\\u003C14 days before first dose of study drug\n    * Any investigational anti-cancer drug therapy within \\\u003C28 days or \\\u003C5 half lives, whichever is shorter\n    * Bisphosphonates or receptor activator of nuclear factor-κB ligand (RANKL) inhibitors initiated, or dose changed \\\u003C1 month prior to first dose of study drug according to institutional guidelines.\n11. Radiation therapy (including CNS directed) within 7 days before the first dose of study drug or without a full recovery from radiotherapy acute effects.\n12. Uncontrolled significant active infections\n\n    * Participants with hepatitis B virus (HBV) and\u002For hepatitis C virus (HCV) infection must have undetectable viral load (or detected below the lower limit of quantification) during screening\n    * Participants known to be human immunodeficiency virus positive (HIV+) are allowed as long as they have undetectable viral load (viral suppression) at baseline.\n13. Major surgery within 4 weeks of starting trial therapy.\n14. Inability to take oral medication, or history of malabsorption syndrome or any other uncontrolled gastrointestinal condition that may significantly alter the absorption of study drugs.\n15. Females of childbearing potential who do not agree to use a highly effective non-hormonal method of contraception and to abstain from donating ova within 28 days of the first dose of study treatment through 120 days after the last dose of study treatment. Highly effective non-hormonal method of contraception includes any of the following:\n\n    1. Intrauterine device (non-hormonal)\n    2. Sexual abstinence\n    3. Bilateral tubal occlusion\u002Fligation\n    4. Have a vasectomized partner with confirmed azoospermia.\n16. Male participants (including males after a vasectomy) with a pregnant or non-pregnant female of childbearing potential partner who do not agree to use a highly effective barrier contraception method (condoms) within 28 days of the first dose of study treatment until 120 days of the last dose of study treatment. And male participants who do not agree to abstain from freezing or donating sperm within the same period. In addition, female partners of childbearing potential, of male participants (who has not undergone vasectomy) must use highly effective methods of contraception.\n17. Females who are pregnant or breastfeeding. Females should not get pregnant during study treatment and for 120 days after last dose of study treatment. Females should not breastfeed during administration of elacestrant and for 1 week after receiving the last dose.\n18. Known intolerance to either study drug or any of their excipients.\n19. Participants currently receiving or received any of the following medications prior to first dose of trial therapy:\n\n    1. Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 (including foods and herbal preparations) within 14 days or \\\u003C5 half-lives, whichever is shorter)\n    2. Herbal preparations\u002Fmedications (which are not strong or moderate inducers or inhibitors of CYP3A4). These include, but are not limited to, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng within 7 days prior to initiating trial therapy\n    3. Vaccination, including but not limited to vaccination against coronavirus disease-19 (COVID-19), during the 7 days prior to randomization.\n20. Any severe medical or psychiatric condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study.","ALL","18 Years",{"count":20,"type":21},73,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose (RP2D) and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in participants with active brain metastases from ER-positive, HER-2 negative breast cancer.",[28,29,30,31,32,33,34,35],"Breast Neoplasms","Brain Neoplasms","Neoplasms by Site","Neoplasms","Breast Diseases","Central Nervous System Neoplasms","Brain Diseases","Central Nervous System Diseases","RECRUITING","2026-06-03",{"date":39,"type":40},"2026-06-04","ACTUAL",{"date":42,"type":40},"2022-08-31",{"date":44,"type":21},"2026-12",{"name":46,"class":47},"Stemline Therapeutics, Inc.","INDUSTRY",86,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100355699","NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* Lesion must be ≥ 1.0 cm ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking\n* Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea)\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to entering this study (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥ 7 days). For viral therapy, patients must have received viral therapy ≥ 3 months prior to study entry and have recovered from all acute toxicities potentially related to the agent.\n* Monoclonal antibodies: The patient must have received last dose ≥ 21 days prior.\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to study entry.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to study entry.\n* Normal hematological, renal and liver function (absolute neutrophil count \\> 1000\u002Fmm3, platelets \\> 100,000\u002Fmm3, prothrombin time (PT) or partial thromboplastin time (PTT) \\\u003C 1.3 x control, creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, total bilirubin \\\u003C 1.5 mg\u002Fdl, transaminases \\\u003C 3 times above the upper limits of the institutional norm)\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Patient life expectancy must be at least 8 weeks\n* Written informed consent in accordance with institutional and FDA guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Any treatment outside the allowable guidelines outlined in section 5.1.\n* Diffuse, widespread, abnormal tumor pattern involving 3 or more lobes of the brain\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or CNS infection \\\u003C 3 months prior, or receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Required steroid increase within 1 week prior to G207 inoculation or patients requiring \\>2 mg of dexamethasone daily\n* Known HIV seropositivity\n* Concurrent therapy with any drug active against HSV (acyclovir, valacyclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone).\n* Other current malignancy\n* Concurrent anticancer or investigational drug","3 Years","21 Years",{"count":58,"type":21},24,[24],"This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[62,63,64,31,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,30,34,35,84,85,86,87,88,89,90],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasm Malignant","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Nervous System Diseases","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[92,93,63,94,95,96,97,98,99,100,101,102,103,104,105,106,31,107,108,109,110,111,112,113,114,87,86,115,116,117],"Brain Tumor, Recurrent","Glioma","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","2026-05-13",{"date":120,"type":40},"2026-05-15",{"date":122,"type":40},"2019-09-12",{"date":124,"type":21},"2027-09-01",{"name":126,"class":127},"M.D. Anderson Cancer Center","OTHER",3,{"id":130,"slug":4,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":150,"locationsCount":152},"100559941","NCT06570681","Video Call Assisted Assessment of Acute Stroke","Video Call Assisted Assessment of Acute Stroke in Addition to Stroke Scales in a Prehospital Setting: A Cluster Randomised Controlled Trial","Inclusion Criteria:\n\n* Suspected stroke within 24 hours from onset (confirmed with Prehospital Stroke 1 decision tool)\n* Age \\>18 years\n\nExclusion Criteria:\n\n* Suspected stroke more than 24 hours ago\n* In-hospital stroke or private transport to hospital\n* Unconsciousness defined as Glasgow Coma Score (GCS) ≤ 8 (as they cannot be rated)",{"count":136,"type":21},512,[138],"NA","This study aims to investigate whether a live stream video between the on-call neurologist and the emergency medical technicians can increase feasibility and performance of symptom-based prehospital stroke scales.",[141,142,34,84,143,35],"Stroke","Cerebrovascular Disorders","Vascular Diseases","2026-05-11",{"date":146,"type":40},"2026-05-14",{"date":148,"type":40},"2024-05-27",{"date":37,"type":21},{"name":151,"class":127},"University of Southern Denmark",1,{"id":154,"slug":4,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":159,"sex":17,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":152},"100442999","NCT05048680","Effect of Hypoxic Conditioning on Cerebrovascular Health in the Elderly","HYPOXAGE","Inclusion Criteria:\n\n* 60 to 80 years of age;\n* Being physically inactive (less than 150 min\u002Fweek of moderate to intense physical activity);\n* No chronic cardiovascular, respiratory, metabolic or neuromuscular disease counterindicating an exercise training or hypoxic conditioning program;\n* Health coverage;\n* Being able to provide written fully informed consent.\n\nExclusion Criteria:\n\n* Body-mass index \\>30 kg\u002Fm2;\n* Smoking (\\> cigarettes\u002Fday);\n* Alcohol use (\\> 10g\u002Fday);\n* Mental disorder or history of mental disorder;\n* Beta-blockade treatment;\n* Inability or refusal to provide informed consent;\n* No health coverage\n* People exceeding the annual ceiling of allowances received as a result of their participation in other clinical trials;\n* People deprived of freedom by judicial or administrative decision;\n* People subject to legal protection, who cannot be included in clinical trials.",true,"60 Years","80 Years",{"count":163,"type":21},64,[138],"In line with the ever-growing aging of Western populations, the development of preventive strategies to slow down the effects of aging on cardiovascular health represents a major challenge in order to preserve functional capacities and a sufficient quality of life in the elderly. The alteration of vascular function (at the cerebral and systemic level) with aging is an important feature in the clinical picture including a decrease in physical and cognitive capacities. Although physical activity is recognized as an essential means of combating the effects of aging, optimizing its effects by defining the most effective strategies of practice remains a key objective. Offering alternative interventions to exercise training is also necessary for people who are unwilling or unable to engage in a physical activity program. In this context, hypoxic conditioning, alone or in conjunction with rehabilitative exercise training, is a new therapeutic modality with strong preclinical validity, in particular from a cardiovascular standpoint, and used in other pathologies to improve cardiovascular function and exercise performance and quality of life. Our aim is, therefore, to investigate the effect of hypoxic conditioning (alone or in conjunction with exercise training) on cerebrovascular health in the elderly.",[167,168,34,169,170,171,172],"Hypoxia","Cerebral Hypoxia","Exercise","Aging","Cognitive Decline","Healthy Aging","2026-05-04",{"date":175,"type":40},"2026-05-08",{"date":177,"type":40},"2021-10-13",{"date":179,"type":21},"2026-09",{"name":181,"class":127},"University Hospital, Grenoble",{"id":183,"slug":4,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":17,"minAge":160,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":200,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":213},"100522861","NCT06088121","Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia","Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study","ATC-P001","Inclusion Criteria:\n\n1. Patients who started drug treatment with an acetylcholinesterase inhibitor at least 2 months before participating in the clinical trial and can participate in the clinical trial without changing the dose during the trial period.\n2. Male or female age 60-85 years.\n3. Patients diagnosed with mild stage of Alzheimer's Disease, according to the NIA-AA (2011) diagnosis.\n4. A patient whose dementia was confirmed to be due to Alzheimer's disease by amyloid PET-CT.\n5. MMSE score 21 to 26.\n6. CDR 1 or GDS 3.\n\n   ※ For subjects who are excluded from screening based on criteria 5 or 6, if the investigator judges that the subject is likely to be eligible, one repeat screening may be performed.\n7. A patient who is deemed physically eligible for the clinical trial based on medical records and physical examination.\n8. A patient who is unable to provide voluntary informed consent for the clinical trial due to impaired decision-making capacity, for whom a legally authorized representative provides consent for participation, and who can attend follow-up visits with a caregiver.\n9. Patients who agreed to participate in all 24-week clinical trials.\n10. Patients with normal ability to see and hear letters.\n11. Patients who speak Korean as their mother tongue\n\nExclusion Criteria:\n\n1. Patients with central nervous system (CNS) disorders that may affect cognitive function (such as cerebrovascular diseases including vascular dementia, subdural hematoma, normal pressure hydrocephalus, brain tumors, CNS infections like HIV or syphilis, head trauma, Huntington's disease, Parkinson's disease, etc.) where cognitive decline may be explained by other causes, or in whom dementia types other than Alzheimer's disease are suspected.\n2. Patients who have been unconscious due to brain surgery or concussion, or who have signs or symptoms of cranial pressure elevation on neurologic examination.\n3. History of Epileptic Seizures or Epilepsy.\n4. Patients with a history of drug abuse, including alcohol, in the past 5 years from the time of screening.\n5. Patients with schizophrenia, schizoaffective disorder, bipolar disorder, current major depressive episode, psychosis, panic, post-traumatic stress, severe anxiety, mental retardation, DSM-V disorder.\n6. Patients with abnormal vitamin B12, folic acid deficiency, or thyroid stimulating hormone (TSH) test results that were considered by the investigator to affect or are caused by the severity of dementia.\n7. Patients with metal implants in the head, (i.e. cochlear implants, implanted brain stimulators and neurostimulators, aneurysm clips) with the exception of metal implants.\n8. Cardiac pacemakers.\n9. Implanted medication pumps.\n10. Intracardiac lines.\n11. Patients who are currently taking medications that lower the convulsive seizure threshold.\n12. Significant heart disease.\n13. Patients with severe renal or hepatic impairment※, referring to conditions that significantly affect daily living (e.g., stage 4 chronic kidney disease), with the assessment based on the investigator's judgment.\n14. Contraindication for performing MRI scanning.\n15. Contraindication for performing amyloid PET-CT scanning.\n16. Patients who do not consent to TMS treatment and participation in this clinical trial.\n17. Patients who participated in other clinical trials 3 months before participating in this clinical trial.\n\n    ※ Subjects who participate in non-interventional studies (such as observational studies) that do not affect the subject's disease or symptoms may be enrolled in the study.\n18. Patients with a history of TMS treatment within the last 2 years before participating in this clinical trial.\n19. Patients judged by the investigator to be unsuitable for participation in clinical trials for other reasons.\n\n    ※ If the test subject is unable to visit according to the research plan due to unavoidable personal circumstances during the screening period, it will be treated as a screening dropout, and the patient can participate in the study after re-agreeing according to the future schedule.\n20. Patients with a history of malignant tumors within the last 5 years.\n\n    \\- Participation is possible if more than 5 years have elapsed without recurrence after the decision to be cured (The point of complete removal of the tumor through surgery or the end of chemotherapy, etc.).\n21. Patients who need to take medications suggested in concomitantly contraindicated drugs.","85 Years",{"count":191,"type":21},180,[138],"The study tests the effect of the ATNC MDD-V1 on Alzheimer patients' cognitive function. The ATNC MDD-V1 uses non-invasive stimulation of both magnetic and cognitive training.",[195,196,34,35,84,197,198,199],"Alzheimer's Disease","Dementia","Neurodegenerative Diseases","Neurocognitive Disorders","Mental Disorder",[201,202,203,196],"TMS","Cognitive Stimulation","ATNC MDD-V1","2026-04-21",{"date":206,"type":40},"2026-04-23",{"date":208,"type":40},"2023-05-15",{"date":210,"type":21},"2027-06-30",{"name":212,"class":47},"Advanced Technology & Communications",11,{"id":215,"slug":4,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":243},"100607166","NCT07185022","Intra-arterial Thrombolysis for Acute Ischemic Stroke With Medium Vessel Occlusion","a Multicenter Prospective Randomized Controlled Trial of Intra-artErial thrombolysiS for aCUte Ischemic strokE With Medium Vessel Occlusion (RESCUE MeVO)","RESCUE MeVO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Primary medium vessel occlusion (MeVO) or severe stenosis (≥70%) was detected on CTA, MRA, or DSA, involving arterial segments including M2-M3 of the middle cerebral artery (MCA), A1-A2 of the anterior cerebral artery (ACA), P1-P2 of the posterior cerebral artery (PCA), and the anterior inferior cerebellar artery (AICA), posterior inferior cerebellar artery (PICA), and superior cerebellar artery (SCA)\n* The clinical symptoms were consistent with MeVO, with a NIHSS score 5 - 25, or an NIHSS score of 3-4 in the presence of disabling neurological deficits (e.g., hemianopia, aphasia, or motor dysfunction)\n* Intra-arterial thrombolysis was administered within the following time windows:\n\n  1. Acute ischemic stroke within 24 hours of symptom onset or last known well, including stroke with known onset, wake-up stroke and stroke with unknown onset, with no obvious hypodensity on CT and good collateral circulation on CTA;\n  2. Acute ischemic stroke within 24-72 hours of onset, meeting at least one of the following imaging criteria: a.CT or MR perfusion imaging demonstrating target mismatch, defined as an ischemic core volume \\\u003C30 mL, a mismatch ratio ≥1.2, and a mismatch volume ≥10 mL.; b.MRI demonstrating DWI-FLAIR mismatch, defined as the presence of acute ischemic lesions on diffusion-weighted imaging (DWI) with no corresponding hyperintense signal on FLAIR, or with FLAIR hyperintense lesions occupying less than one-third of the DWI lesion volume.\n* Signed informed consent obtained\n\nExclusion Criteria:\n\n* Pre-stroke mRS ≥ 2\n* Secondary MeVO or severe stenosis caused by endovascular therapy\n* Neuroimaging demonstrated intracranial hemorrhage, subarachnoid hemorrhage, or other hemorrhagic disorders\n* Non-contrast CT demonstrating a clearly hypodense lesion corresponding to the vascular territory\n* Platelet count \\\u003C100 × 10⁹\u002FL, known bleeding tendency or coagulation factor deficiency, or oral anticoagulant therapy with an international normalized ratio (INR) \\>3.0\n* Persistent and uncontrolled hypertension, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg\n* History of intracranial hemorrhage within the past 3 months, including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, epidural hemorrhage, or subdural hemorrhage\n* Presence of arteriovenous malformations or brain tumors with mass effect\n* Gastrointestinal or urinary tract bleeding, or major surgery within the past 3 months\n* Chronic dialysis or severe renal impairment, defined as a glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine \\>220 μmol\u002FL (2.5 mg\u002FdL)\n* Patients with known allergy to thrombolytic agents or their excipients\n* Patients with known allergy to iodinated contrast agents or other established contraindications\n* Pregnant or current breastfeeding\n* Presence of severe systemic comorbidities with a life expectancy of less than 3 months\n* Deemed unsuitable for participation by the investigator for any reason",{"count":222,"type":21},282,[138],"Acute ischemic stroke (AIS) due to medium vessel occlusion (MeVO) or severe stenosis poses a significant clinical challenge. Recent large randomized controlled trials, DISTAL and ESCAPE-MeVO, demonstrated no significant benefit of endovascular therapy in patients with MeVO. Although intra-arterial thrombolysis has shown promise in clinical experience, robust evidence supporting its efficacy in MeVO or severe stenosis-related AIS is still absent. To fill this gap, the RESCUE MeVO trial has been designed as a multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study to evaluate the efficacy and safety of intra-arterial thrombolysis in patients with AIS caused by MeVO or severe stenosis.",[141,142,34,84,143,226,227,228],"Ischemic Stroke","Infarction","Medium Vessel Occlusion",[230,231,141,232,233],"Ischemic stroke","Medium vessel occlusion","Intra-arterial thrombolysis","Severe stenosis","2026-04-13",{"date":236,"type":40},"2026-04-16",{"date":238,"type":40},"2026-01-06",{"date":240,"type":21},"2030-05-01",{"name":242,"class":127},"The Second Hospital of Anhui Medical University",6,{"id":245,"slug":4,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":265,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":152},"100576378","NCT06784518","Stroke Cerebral Reorganization Pathways (SPECTRE)","Stroke Cerebral Reorganization Pathways Longitudinal Study After Stroke of the Clinical Motor Pattern and the Cerebral Reorganization According to the Different Damaged Motor Pathways (Main and Accessory) (SPECTRE)","SPECTRE","Inclusion Criteria:\n\n* Adult (age greater than or equal to 18 years) less than 75 years of age, both sexes;\n* single supratentorial ischemic stroke confirmed by brain imaging\n* Upper limb deficit defined by a SAFE score \\\u003C5 (SAFE Stinear protocol, prognosis of post-stroke upper limb recovery) on D3 of stroke. This corresponds to the sum of shoulder abduction and finger extension according to the MRC (Medical Research Council) scale for each of these movements out of 5.\n* Absence of comprehension disorders limiting participation;\n* Patient covered by french social security;\n* Free, informed and written consent signed by the patient or a member of the patient's family (in the case of a patient who is able to understand the information and give consent but has motor difficulties resulting in an invalid signature).\n\nNon-Inclusion Criteria:\n\n* Multiple ischemic strokes or history of clinically significant stroke ;\n* Posterior fossa stroke ;\n* Hemorrhagic stroke;\n* Patient who have undergone thrombolysis or mechanical thrombectomy;\n* Extensive Fazekas grade 3 vascular leukopathy;\n* Pre-existing neurodegenerative pathology;\n* Patient with severe dyspnea or swallowing disorders who cannot undergo brain MRI;\n* Adults under legal protection (safeguard of justice, curatorship, guardianship, family habilitation), persons deprived of liberty;\n* Women declaring that they are pregnant or breast-feeding;\n* Patient participating in another therapeutic or drug intervention study that may have an impact on the effect of cerebral neuroplasticity on the SPECTRE study;\n* Patients with contraindications to MRI pacemaker or implantable defibrillator, neurosurgical clips, cochlear implants, intra-orbital or encephalic metallic foreign bodies, stents placed less than 4 weeks ago and osteosynthesis devices placed less than 6 weeks ago, claustrophobia.\n\nExclusion Criteria:\n\n* If the prognostic group according to the PREP2 algorithm (good, limited and poor) has already been reached during motor evoked potential assessment the patient is excluded.\n* Recurrence of clinically significant stroke (with worsening NIHSS score \\> 4) during study.","75 Years",{"count":253,"type":21},30,[138],"SPECTRE is a prospective longitudinal study in order to identify whether patients with different degrees of motor recovery are distinguished by distinct brain post-stroke plasticity patterns in the acute and sub-acute phases. This study allows close longitudinal follow-up of patients with severe clinical motor impairment using functional MRI to study cerebral neuroplasticity after ischemic stroke in the acute and sub-acute phase in patients with upper limb motor impairement, taking into account prognostic criteria used in current practice.",[34,226,141,257,258],"Brain Infarction","Stroke Rehabilitation",[260,261,262,263,264],"stroke","Rehabilitation","Upper Limb","Neuroplasticity","Connectivity","NOT_YET_RECRUITING","2026-03-27",{"date":268,"type":40},"2026-04-02",{"date":270,"type":21},"2026-09-01",{"date":272,"type":21},"2029-03",{"name":274,"class":127},"Rennes University Hospital",{"id":276,"slug":4,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":283,"phases":4,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":128},"100483689","NCT05578300","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific","Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific: a Multicenter, Prospective Registry (ENDURE-APAC)","Inclusion Criteria:\n\n* Patient who are over 18 years of age.\n* Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA).\n\nExclusion Criteria:\n\n* Patient with isolated vertebral artery occlusion not involving the BA.",{"count":282,"type":21},350,"OBSERVATIONAL","As a major breakthrough of acute stroke treatment over the past decade, endovascular thrombectomy (EVT) drastically improved neurological recovery and survival in patients with large vessel occlusion (LVO) ischemic strokes in major clinical trials. Nevertheless, much remained uncertain about the implementation of scientific evidence of EVT into real-world benefits. For instance, healthcare policies that influence critical time-matrices, endovascular thrombectomy techniques that may enhance success rate or prevent complications, or advanced imaging techniques that allow precise prognosis or expansion of treatment populations, should be evaluated. On the other hand, capturing LVO patients who were not able to undergo EVT may reveal the gap between clinical trials and real-world practice in the Asia-Pacific.\n\nIn this multicenter prospective collaboration across the Asian-Pacific, the investigators aim to evaluate the determinants of effective EVT in the real-world setting.",[226,141,286,287,34,288],"Stroke, Acute","Stroke, Ischemic","Major Adverse Cardiovascular Event","2026-03-16",{"date":291,"type":40},"2026-03-18",{"date":293,"type":40},"2022-10-21",{"date":295,"type":21},"2032-12-31",{"name":297,"class":127},"Chinese University of Hong Kong",{"id":299,"slug":4,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":313,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":152},"100337803","NCT03678194","Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application","Treating Depression on a Day-to-day Basis: Development of a Novel Clinical Tool for Physicians Based on a Smartphone Application, the SMART Project (Smartphones and Mood Disorders, an Application for Research and Treatment)","SMART","Inclusion Criteria:\n\n* Age between 18 and 65 years;\n* Fulfilling the Diagnostic and Statistical Manual version IV (DSM-IV) criteria of depression assessed by the Structured Clinical Interview;\n* Patients started their antidepressant treatment less than 5 days before inclusion;\n* Patient treated in an outpatient setting;\n* Patient informed of the diagnosis of his disease;\n* Informed patient with written consent.\n\nExclusion Criteria:\n\n* A current mental or psychiatric impairment or disease (schizophrenia, bipolar disorder) that required psychotropic medication or inpatient treatment on a psychiatric ward;\n* A history of psychosis, including schizophrenia, bipolar I or bipolar II disorder, and major depressive disorder with psychotic features;\n* Cognitive deficit and not thus being able to comprehend the informed consent and study procedure;\n* Patients with somatic, cognitive or other disorders preventing the use of the device (deafness, impaired vision, illiteracy….);\n* Non-comprehension of the French language","65 Years",{"count":307,"type":21},200,[138],"Testing and validating an e-health (smartphone application) approach to better understand the determinants of day-to-day symptomatology in depression, medication adherence, and treatment efficacy in the goal of maximizing patient care.",[311,312,34,35,84],"Depression","Psychiatric Disorder",[311,314,315,316,317,318,319,320],"Smartphone","Relapse prevention","Mobile support system","eHealth","Ecological","Randomized","Multicentric","2026-03-13",{"date":289,"type":40},{"date":324,"type":40},"2020-10-14",{"date":326,"type":21},"2026-12-31",{"name":328,"class":329},"Centre Hospitalier Charles Perrens, Bordeaux","OTHER_GOV",{"id":331,"slug":4,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":347,"overallStatus":265,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":152},"100627679","NCT07451769","Selective Activation of the Adrenomedullin Receptors in Migraine","Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study","Inclusion Criteria:\n\n1. Written informed consent has been obtained prior to the initiation of any study-specific procedures.\n2. Age ≥18 years at the time of screening.\n3. History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and\u002For patient self-report, and diagnosed in accordance with the ICHD-3 criteria.\n\nExclusion Criteria:\n\n1. History of any other primary headache disorder, except for tension-type headache with \\\u003C5 headache days per month, based on ICHD-3 classification.\n2. History of any secondary headache disorder, per ICHD-3 criteria, prior to screening.\n3. Use of prophylactic migraine medication within 30 days or within 5 plasma half-lives (whichever is longer) prior to screening.\n4. Previous use of any therapies targeting the CGRP signaling pathway, including anti-CGRP ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, or small molecule CGRP receptor antagonists.\n5. Known risk of self-harm or harm to others, including a history of suicidal behavior.\n6. Any clinically significant disorder, condition, or disease (other than those permitted in the protocol) that, in the opinion of the investigator, could compromise participant safety or interfere with study procedures or data integrity.\n7. Positive urine pregnancy test at screening or on Day 1 in female participants of childbearing potential.\n8. Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study period.\n9. Evidence of current pregnancy or breastfeeding based on self-report or medical records.\n10. Inability or unwillingness to complete all protocol-required visits and procedures, or concerns regarding protocol adherence, as judged by the investigator.",{"count":337,"type":21},26,[138],"Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.",[341,34,35,342,343,344,345,346],"Migraine","Adrenomedullin","Pain","Peptides","Neuropeptides","Signs and Symptoms",[348,349,343],"Migraine Disorders","Adrenomedulin","2026-03-05",{"date":352,"type":40},"2026-03-09",{"date":354,"type":21},"2026-03-10",{"date":356,"type":21},"2032-12-20",{"name":358,"class":127},"Danish Headache Center",{"id":360,"slug":4,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":159,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":283,"phases":4,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":152},"100438662","NCT04992195","Impact of COVID-19 Vaccines on Cerebrovascular Health","Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study","Inclusion Criteria:\n\nAll consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.\n\nExclusion Criteria:\n\n1. Citizens with clinically evident stroke or dementia prior to recruitment; or\n2. Citizens who are unable to provide an informed consent; or\n3. Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or\n4. Citizens who had no baseline MRI brain assessment.",{"count":366,"type":21},500,"Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.\n\nOn the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise \"young-and-fit\" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health.\n\nIn this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.",[141,286,287,196,369,370,34,288,371,372],"Brain Ischemia","Alzheimer Disease","Arterial Thromboembolism","Venous Thromboembolism","2026-02-21",{"date":375,"type":40},"2026-02-24",{"date":377,"type":40},"2021-07-05",{"date":326,"type":21},{"name":297,"class":127},{"id":381,"slug":4,"hasResults":11,"nctId":382,"briefTitle":383,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":159,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":386,"targetDuration":4,"studyType":283,"phases":4,"briefSummary":388,"conditions":389,"keywords":394,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":405},"100331231","NCT03592563","CUHK Brain Health Longitudinal Study","BHS","Inclusion Criteria:\n\n1. Adult ≥ 18 years of age\n2. Fulfilling criteria for membership in one of these three groups:\n\n   * Red group: established diagnosis of one or more neurological and\u002For psychiatric conditions\n   * Yellow group: high-risk to develop one or more neurological and\u002For psychiatric conditions\n\n     1. family history (first degree relative) one or more neurological and\u002For psychiatric conditions\n     2. examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and\u002For psychiatric disorders\n   * Green group: not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and\u002For improvement of brain health\n3. Subject provides informed consent by signing and dating the written informed consent form\n4. Subject is willing to answer health questionnaires and be followed longitudinally\n\nExclusion Criteria:\n\n* None",{"count":387,"type":21},5000,"The goal of this study is to develop a large longitudinal cohort of individuals diagnosed with or at high risk for brain diseases (both neurological and psychiatric in nature), in order to identify risk factors that contribute to neurological and psychiatric diseases over time. The investigators seek to capture relevant information from medical records, electronically administered questionnaires and follow up phone-based interviews. The investigators expect to eventually have sufficient power from our dataset to examine risk factors for a variety of brain disorders, both individually and in aggregate. Our ultimate goal is to offer scientifically validated ways to preserve and promote brain health by working with our patients' needs and tracking their progress over time.",[287,390,141,286,196,369,34,370,391,392,393,172],"Stroke Syndrome","Health Attitude","Health Knowledge, Attitudes, Practice","Health Personnel Attitude",[260,395,396,397,398],"dementia","Alzheimer disease","Health Brain","Health knowledge",{"date":375,"type":40},{"date":401,"type":40},"2019-07-01",{"date":403,"type":21},"2048-12-31",{"name":297,"class":127},2,{"id":407,"slug":4,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":283,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":152},"100616464","NCT07305948","Evaluation of a New MRI Technique to Reduce Breathing-Related Artifacts in Brain Imaging","Prospective Evaluation of a Free Induction Decay (FID) Navigator-Based Off-Resonance Correction Method (DORK) for Improving High-Resolution 3D Echo Planar (EPI) Susceptibility-Weighted (SWI) Brain MRI","DORK","Inclusion Criteria:\n\n* Adult patients (18 years or older)\n* Undergoing a routine clinical brain MRI at Karolinska University Hospital\n* Able to understand the study information and provide written informed consent\n* Sequence parameters and scan protocol compatible with the research acquisition (3D-EPI SWI)\n\nExclusion Criteria:\n\n* Patients unable to give informed consent\n* Standard contraindications to MRI (e.g., non-MRI safe implants, severe claustrophobia)\n* Clinical conditions requiring urgent imaging where research consent is not feasible\n* Significant motion or incomplete scans preventing creation of research images (rare)",{"count":414,"type":21},100,"This study aims to improve the quality of brain magnetic resonance imaging (MRI) scans by testing a new imaging method that reduces distortions caused by breathing. During respiration, small movements of the chest and diaphragm can lead to subtle changes in the magnetic field within the head. These changes can introduce artifacts in certain MRI techniques, particularly susceptibility-weighted imaging (SWI), which is used to visualize veins, small hemorrhages, and iron deposits.\n\nThe investigated method measures breathing-related magnetic field variations during MRI acquisition using two very short navigator signals, referred to as free induction decay (FID) navigators. These signals are used to perform dynamic off-resonance correction during image reconstruction, reducing image blurring and distortion. The method does not increase scan time and does not affect standard clinical imaging.\n\nIn this study, patients scheduled for routine clinical brain MRI are asked to provide informed consent for use of their raw MRI data for research purposes. For each participant, two sets of SWI images are generated from the same acquisition: one using standard reconstruction and one using the free induction decay navigator-based dynamic off-resonance correction method (FID-DORK). The objective is to assess whether the corrected images provide improved image quality and diagnostic reliability.\n\nThe study includes adult patients undergoing routine clinical MRI at Karolinska University Hospital. Image quality is evaluated using both visual assessment by neuroradiologists and quantitative measures of image variation. No additional imaging procedures, contrast agents, or scan time are required. All research data are pseudonymized prior to analysis.\n\nThe hypothesis is that the dual free induction decay navigator-based correction method (FID-DORK) improves the diagnostic quality of high-resolution three-dimensional echo-planar imaging susceptibility-weighted imaging brain MRI by reducing breathing-related artifacts.",[34],"2026-01-29",{"date":419,"type":40},"2026-02-02",{"date":421,"type":21},"2026-01-05",{"date":423,"type":21},"2027-12-31",{"name":425,"class":329},"Region Stockholm",{"id":427,"slug":4,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":432,"targetDuration":434,"studyType":283,"phases":4,"briefSummary":435,"conditions":436,"keywords":441,"overallStatus":265,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":152},"100620139","NCT07353736","Cerebral Arteriovenous Malformation With Aneurysm: Epidemiology, Clinical Features, and Prognosis","Hemodynamic Mechanisms, Clinical Profiles, and Prognostic Factors in Patients With Cerebral Arteriovenous Malformations and Intracranial Aneurysms: An Observational Cohort Study","Inclusion Criteria:\n\n* Patients diagnosed with cerebral arteriovenous malformation and intracranial aneurysm confirmed by CTA, MRA, and\u002For DSA;\n* Availability of complete clinical and imaging data;\n* Provision of written informed consent by the patient or their legally authorized representative to participate in the study and undergo follow-up;\n* Not concurrently participating in any other clinical trials that may interfere with the outcomes of this study.\n\nExclusion Criteria:\n\n* Previous complete occlusion of the aneurysm and\u002For arteriovenous malformation prior to enrollment;\n* Coexistence of other cerebrovascular diseases such as moyamoya disease, cerebral cavernous malformation, cerebral venous sinus thrombosis, etc.;\n* Absence of DSA imaging data or poor image quality that precludes accurate evaluation of key anatomical and hemodynamic parameters of the AVM and intracranial aneurysm.",{"count":433,"type":21},630,"2 Years","The study is a multicenter, prospective cohort study designed to assess the natural history, clinical safety and efficacy of various treatment strategies in patients with cerebral arteriovenous malformations (AVMs) and intracranial aneurysms.",[437,438,439,440,34],"Cerebral Arteriovenous Malformation","Intracranial Arterial Diseases","Intra Cerebral Hemorrhage","Intracranial Aneurysm",[442,443,444,437,440],"Hemodynamic Mechanisms","Prospective cohort study","Endovascular treatment","2026-01-17",{"date":447,"type":40},"2026-01-20",{"date":449,"type":21},"2026-02-01",{"date":451,"type":21},"2030-12-30",{"name":453,"class":127},"Duan Chuanzhi",{"id":455,"slug":4,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":159,"sex":17,"minAge":460,"maxAge":161,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":463,"briefSummary":464,"conditions":465,"keywords":472,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":152},"100617877","NCT07324330","Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity","ALPHA-FIT","Inclusion Criteria:\n\niRBD:\n\n* Age: 50-80 years\n* Polysomnographically confirmed diagnosis of iRBD\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nHealthy controls:\n\n* Age: 50-80 years\n* Maximum of 120 minutes of sports\u002Foutdoor activities per day\n* Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase\n* Basic smartphone skills\n* Sufficient knowledge of German (native language, C1 or C2)\n* Ownership of a suitable smartphone (minimum screen size 4.6 inches, Android version 9 or iOS version 15 or newer)\n* Consent to be informed of any additional findings\n\nExclusion Criteria:\n\niRBD:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n\nHealthy controls:\n\n* Relevant cardiovascular diseases\n* Problems with dexterity or cognitive impairments that make it difficult to use a smartphone\n* Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study\n* Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)\n* clinically diagnosed iRBD","50 Years",{"count":462,"type":21},130,[138],"α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before relevant motor or cognitive disorders are present. Therapeutic interventions in individuals with iRBD therefore have great preventive potential. In particular, increasing physical activity could have a relevant effect on neurodegenerative processes, including the preservation of cognitive functions.\n\nThe aim of the study is therefore to investigate the effects of increased physical activity in everyday life on cognitive functions in individuals with iRBD. In this randomized, double-blind, actively controlled study, an increase in physical activity will be implemented over a period of one year with the help of a motivational smartphone application. The intervention and control conditions are the same as those used in the Slow-SPEED trials, making the connection between the trials concrete. The primary outcome parameter is the change in cognitive performance in a neuropsychological test battery over one year.\n\nEighty individuals with iRBD and 50 age- and gender-matched individuals are being recruited at the University Hospital Bonn and the \"Deutsches Zentrum für Neurodegenerative Erkrankungen\" (DZNE) Bonn (German branch only). In addition to classic neuropsychological tests as the primary endpoint, magnetic resonance imaging (MRI) and blood-based markers of brain aging are being examined as secondary endpoints. This study is in close collaboration with the Slow-SPEED study (https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06993142). In addition, selected data from three separate trials-Alpha-Fit, Slow-SPEED-NL, and a sister trial in Austria currently in preparation-are planned to be synthesized into a meta-analysis.",[466,467,197,468,35,469,84,470,34,471],"Parkinson Disease","Prodromal Stage","Basal Ganglia Diseases","Synucleinopathies","Cerebral Disorder","Parkinsonian Disorders",[473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,395],"intervention","movement","iRBD","prodromal parkinson's","non-pharmacologic","alpha-synucleinopathy","biomarker","cognitive decline","executive function","MRI","lifestyle","prevention","RCT","motor decline","smartphone","smartwatch","accelerometer","scalable","prodromal","PD","Parkinson","Lewy-body","MSA","multiple system atrophy","2026-01-14",{"date":499,"type":40},"2026-01-16",{"date":501,"type":40},"2025-12-04",{"date":503,"type":21},"2029-12-01",{"name":505,"class":127},"University Hospital, Bonn",{"id":507,"slug":4,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":511,"eligibilityCriteria":512,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":513,"targetDuration":4,"studyType":283,"phases":4,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":152},"100620071","NCT07352852","Rapamycin-Eluting Vertebral Stents In The Real-World Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","Rapamycin-eluting Vertebral Stents in the Real-world Treatment of Symptomatic Intracranial Atherosclerotic Stenosis","BRIDGE-INTRA","Inclusion Criteria:\n\n* Age ≥18 and ≤80 years;\n* Symptomatic intracranial atherosclerotic stenosis patients with ineffective medical treatment;\n* Digital subtraction angiography (DSA) shows target lesion stenosis ≥70%;\n* Suitable for implantation of rapamycin-targeted drug-eluting stents;\n* The patient and\u002For their authorized representative can understand the study purpose, agree to participate, and sign the informed consent form.\n\nExclusion Criteria:\n\n* Modified Rankin Scale (mRS) score ≥3;\n* Ischemic stroke within the past 2 weeks;\n* Presence of more than 2 intracranial atherosclerotic stenosis lesions requiring interventional treatment;\n* Severe contraindications to heparin, aspirin, ticagrelor, clopidogrel, or other antiplatelet drugs, and inability to tolerate anticoagulant\u002Fantiplatelet therapy;\n* Severe dysfunction of major organs (e.g., severe hepatic insufficiency, renal insufficiency, heart failure);\n* Severe allergies to contrast agents, rapamycin and its derivatives, cobalt-based alloys, or polylactic acid;\n* Pregnant or lactating women;\n* Participation in other drug or device studies without reaching the endpoint;\n* Life expectancy less than 12 months;\n* Lesions or vascular access deemed unsuitable for rapamycin drug-eluting stent implantation by the operator.",{"count":514,"type":21},300,"This clinical trial is a prospective, multicenter, single-arm study. About 300 subjects undergoing rapamycin-eluting stent implantation will be enrolled based on the inclusion and exclusion criteria. The primary endpoint is the rate of any stroke or death within 1 month. Secondary efficacy endpoints include immediate stent implantation success. Safety endpoints cover the incidence of stroke or neurological death, target-vessel-related stroke or death, all-cause mortality, and mRS scores at 12-month follow-ups. Subjects will be clinically followed up before surgery, device implantation, discharge, and at 1, 6, and 12 months post-surgery. An imaging subgroup of at least 80 subjects who agree to DSA follow-up at 12 months will assess in-stent restenosis (\\>50%).",[517,34],"Intracranial Arterial Stenosis","2026-01-13",{"date":447,"type":40},{"date":521,"type":40},"2025-05-14",{"date":523,"type":21},"2028-12-31",{"name":525,"class":127},"The Affiliated Hospital of Qingdao University",{"id":527,"slug":4,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":534,"briefSummary":535,"conditions":536,"keywords":548,"overallStatus":265,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":152},"100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache",{"count":533,"type":21},21,[138],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[537,34,538,84,35,539,346,540,541,343,542,543,544,344,545,546,547],"Headache Disorders, Secondary","Headache Disorders","Neurologic Manifestations","Pathological Conditions, Signs and Symptoms","Post-Traumatic Headache","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[549,343,546],"Post-traumatic headache",{"date":497,"type":40},{"date":552,"type":21},"2026-02",{"date":554,"type":21},"2028-12",{"name":358,"class":127},{"id":557,"slug":4,"hasResults":11,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":562,"targetDuration":4,"studyType":22,"phases":563,"briefSummary":564,"conditions":565,"keywords":568,"overallStatus":265,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":571,"leadSponsor":573,"locationsCount":152},"100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":533,"type":21},[138],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[566,538,34,84,35,539,346,540,348,567,343,542,543,544,344,545,546,547],"Headache Disorders, Primary","Headache",[341,567,343,546],{"date":497,"type":40},{"date":552,"type":21},{"date":572,"type":21},"2028-10-30",{"name":358,"class":127},{"id":575,"slug":4,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":578,"eligibilityCriteria":579,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":22,"phases":582,"briefSummary":583,"conditions":584,"keywords":586,"overallStatus":265,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":4},"100618712","NCT07335185","Gravity Stroke System for Recanalization of Large Vessel Occlusion Strokes","GRASSROOT Reg","Inclusion Criteria:\n\n1. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral artery.\n2. Subject has been or will be treated with Supernova and\u002For Neutron devices as the initial device used to remove the thrombus\n3. Subject is willing to participate in a 90-day follow-up visit.\n\nExclusion Criteria:\n\n* Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm where the study procedure or treatment might confound the results of the registry.",{"count":581,"type":21},3000,[138],"Supernova and Neutron are endovascular mechanical revascularization devices indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing an acute ischemic stroke within 24 hours of symptom onset or from last known well time.",[141,226,142,34,35,84,585],"Vascular Disease",[587,588,589,590,257,591,592,593,594,595,141,596],"Mechanical Thrombectomy","Brain","Brain Clot","Cerebral Ischemia","Neurovascular Intervention","Revascularization","Reperfusion","Stent Retriever","Supernova","Gravity Medical Technology",{"date":518,"type":40},{"date":599,"type":21},"2026-01-01",{"date":601,"type":21},"2030-12-31",{"name":603,"class":47},"Gravity Medical Technology, INC",{"id":605,"slug":4,"hasResults":11,"nctId":606,"briefTitle":607,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":22,"phases":611,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":152},"100615113","NCT07288385","Investigating the Feasibility of Combining Virtual Reality and Bilateral Transcranial Direct Stimulation to Improve Upper Limb Recovery in Patients With Stroke","bi-tDCS+VR","Inclusion Criteria: 1- Adult participants (over 18 years of age) (Elsner et al., 2020).\n\n2- Patients with a unilateral cerebral infarction or haemorrhage who are at least three months post-stroke (Muller et al., 2021).\n\n3- Adequate mental status confirmed by an MMSE (Arabic version) should be ≥24 (Kim, 2021). ensuring the ability to comprehend and follow instructions.\n\n4- Modified Ashworth scale score \\\u003C 3 (Ögün et al., 2019). 5- Fugl-Meyer assessment (FMA) scores between 29 and 58, indicating moderate impairments (Woytowicz et al., 2017).\n\n\\-\n\nExclusion Criteria: - Visual impairment and severe hemisensory neglect or inattention (Stahl et al., 2019; Fluet1 et al., 2015).\n\n2- Individuals who have aphasia find it difficult to follow instructions (Fluet et al., 2015).\n\n3- Presence of any medical condition that contraindicates the use of non-invasive brain stimulation (Stahl et al., 2019; Learmonth et al., 2021).\n\n4- History of neurological disorders unrelated to stroke or participation in another study.\n\n\\-",{"count":414,"type":21},[138],"Following a stroke, the function of the distal upper limb, especially hand and finger movements, is often severely compromised, significantly restricting the ability to carry out daily activities. It is estimated that 55-75% of stroke survivors suffer from motor dysfunction, with upper limb impairments affecting up to 85% of them (Tang et al., 2024). Current rehabilitation approaches, while beneficial, often produce limited gains in hand function, particularly in patients with chronic stroke. Virtual reality (VR) training has emerged as a promising tool in neurorehabilitation, providing repetitive, task-specific, and engaging practice environments that can promote motor learning (Cameirão et al., 2012). tDCS has also shown potential to enhance motor recovery when combined with motor practice (Kang et al., 2016). To date, no studies have directly compared the effectiveness of Bi-tDCS with VR for improving upper limb function after stroke.",[34,35,84,141,614],"Paresis",[616,617,618,619,620,621,622,623,624,141],"ischemic stroke","Hemorrhagic stroke","bi-tDCS","Hemiparesis","Neural activation","Primary motor cortex","NIBS","Non-invasive brain stimulation","Transcranial direct current stimulation","2025-12-29",{"date":627,"type":40},"2025-12-30",{"date":629,"type":40},"2025-12-28",{"date":631,"type":21},"2027-01-30",{"name":633,"class":127},"King Saud University",{"id":635,"slug":4,"hasResults":11,"nctId":636,"briefTitle":637,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":22,"phases":642,"briefSummary":643,"conditions":644,"keywords":645,"overallStatus":265,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":654,"leadSponsor":656,"locationsCount":152},"100566152","NCT06651463","Evaluation of the Feasibility of Camera Measurement of Colorimetric Parameters of the Brain During Neurosurgery Operations: Tissue Oximetry and Endogenous or Induced Fluorescence","NEUROVISION","Inclusion Criteria:\n\n* Adult from both sex\n* Neurosurgery requiring a functional diagnosis by cortical electrical stimulation OR a histological diagnosis with or without fluorescent agent (5-ALA) for a tumor pathology or epilepsy or an arteriovenous malformation.\n* Patient able to sign a non-opposition\n\nExclusion Criteria:\n\n* Impaired renal function defined by the presence of creatinine clearance less than 30ml\u002Fmin\n* Patient under treatment with beta-blocker\n* Contraindication to performing an MRI (pacemaker)\n* Contraindication to the use of electrical cortical stimulation\n* History of life-threatening allergic reactions or known hypersensitivity to 5-ALA\n* Pregnant, breastfeeding woman\n* Subject participating in another interventional research including an exclusion period still ongoing at pre-inclusion,…\n* Persons deprived of liberty by a judicial or administrative decision\n* People receiving psychiatric care\n* Persons admitted to a health or social establishment for purposes other than research\n* Adults subject to a legal protection measure (guardianship, curatorship)\n* Persons not affiliated to a social security scheme or beneficiaries of a similar scheme",{"count":641,"type":21},50,[138],"The management of many brain pathologies involves obtaining a functional and histological diagnosis and performing neurosurgery when possible. Histological diagnosis makes it possible to differentiate healthy areas from pathological areas. Functional diagnosis allows the identification of brain areas to be spared during neurosurgery in order to avoid any permanent post-operative disability.\n\nThe visual analysis of the color and texture of the brain by the trained eye of the neurosurgeon is largely part of his operating practice. It allows it to differentiate between healthy and pathological areas. Likewise, color variations linked to the functional activation of brain areas are sometimes visible to the naked eye. However, this approach is not optimal due to the limits of human vision. It is also very strongly dependent on the experience and expertise acquired by the neurosurgeon. This approach is therefore largely limited in many operating contexts: low visual contrasts, less experienced neurosurgeon.",[34],[646,647,648,649],"feasibility","tissue identification","neurosurgery","video","2025-12-11",{"date":652,"type":40},"2025-12-18",{"date":599,"type":21},{"date":655,"type":21},"2028-01-01",{"name":657,"class":127},"Hospices Civils de Lyon",{"id":659,"slug":4,"hasResults":11,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":665,"targetDuration":666,"studyType":283,"phases":4,"briefSummary":667,"conditions":668,"keywords":675,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":152},"100589453","NCT06954610","Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent (by patient, next of kin or legally authorised representative)\n* Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation\n* Acute (≤7 days), symptomatic ischemic stroke\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Patient is unlikely to attend follow-up visits",{"count":366,"type":21},"12 Months","Background\n\nAtrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke, accounting for approximately one third of cases. Oral anticoagulant therapy (OAC) is a cornerstone in stroke prevention in patients with AF. According to randomized controlled trials of direct oral anticoagulants, a residual risk of ischemic stroke of 1-2% per year for so-called \"breakthrough stroke\" remains, despite adequate intake of OAC. The majority (\\>70%) of these breakthrough strokes are cardioembolic in nature and only a minority are related to medication issues (e.g. non-compliance) or other, non-AF related etiologies. Stroke recurrence risk after such a breakthrough stroke markedly increases to 8-9% per year indicating a particularly high-risk situation. Why OAC fails in certain patients, but not in others remains as poorly understood, as does the reason why the subsequent risk of stroke is so high.\n\nCurrent risk stratification tools, such as the widely used CHA2DS2-VA(Sc)-score, fail to predict stroke risk in such a high-risk cohort, as they were intended to guide the initiation of OAC in low to moderate risk patients. In light of new therapeutic strategies currently being investigated, such as percutaneous left atrial appendage occlusion in patients with breakthrough strokes (ELAPSE - NCT05976685) or in AF-patients deemed high-risk (LAAOS IV - NCT05963698), improved risk stratification and characterization of high-risk AF patients is highly warranted.\n\nSeveral clinical factors, such as those reflected in the CHA2DS2-VA(Sc)-score, and especially a high AF-burden are associated with increased risk of cardioembolic stroke. Several cardiac serum biomarkers are thought to be surrogates not only of cardiac function, but also of cardioembolic risk. Reflecting ventricular and atrial wall tension, myocardial injury, oxidative stress and thrombogenicity, elevated NT-proBNP, MR-proANP, high-sensitive Troponin T and D-Dimers have all been associated with cardioembolic stroke in different AF and non-AF populations. As the main location of thrombus formation, the left atrium (LA) and more specifically its appendage (LAA) are of particular interest in the pathogenesis of cardioembolism. Pronounced LA-enlargement, compared to a normal-sized LA, correlates with an increased risk of cardioembolism in AF-patients. As over 80% of thrombi form within the LAA, several LAA-characteristics, such as slower LAA-flow velocity and larger LAA-orifice area have also been demonstrated to be associated with higher stroke risk. Although there is data on each one of these factors, they have only been investigated in low to moderate risk populations, such as AF-patients without prior stroke, OAC-naïve patients, or even within the general population as a whole. Their role in high-risk AF-patients and in breakthrough stroke is unknown.\n\nHypothesis\n\nThe investigators hypothesize that specific clinical factors, serum cardiac biomarkers and markers of LA- and LAA-morphology and function are associated with breakthrough stroke \u002F OAC-failure and may improve risk stratification.\n\nMethods\n\nCARE-AF is a single-center, prospective cohort study conducted at the Stroke Center of the Inselspital, University Hospital Bern, Switzerland. Patients with an index ischemic stroke and AF (breakthrough and non-breakthrough cases) will be enrolled. The investigators will collect clinical data, serum cardiac biomarkers and echocardiographic indices of the LA and LAA. All patients will receive standardized annual follow-ups until the end of the study, defined as 12 months after the inclusion of the last participant. The primary endpoint is ischemic stroke or systemic embolism during follow-up. First, in a cross-sectional design, the study will assess the association between serum cardiac biomarkers and echocardiographic indices among patients with breakthrough vs. non-breakthrough stroke as index event, applying multivariate regression models. Second, the investigators will perform a longitudinal analysis assessing the association between the variables mentioned above and breakthrough stroke as index event with the primary endpoint, using multivariate Cox regression models. The study aims to enroll a minimum of 500 patients, which provides sufficient power to detect a clinically meaningful adjusted hazard ratio for recurrent stroke of 1.5 with 80% power at an alpha level of 5%.\n\nConclusion\n\nThe results of this project will enhance understanding of the role of specific clinical factors, cardiac serum biomarkers and echocardiographic indices in the residual risk of stroke in patients with AF on anticoagulation therapy. They may improve current risk stratification and have the potential to help guide therapeutic decisions in high-risk situations considering evolving therapeutic possibilities.",[226,669,142,34,35,143,670,671,257,369,672,141,673,674],"Atrial Fibrillation","Arrhythmias, Cardiac","Heart Diseases","Infarction Cerebral","Cardioembolic Stroke","Ischemia",[230,676,677,678,679,680,681,682],"Direct oral anticoagulation","Anticoagulation","Breakthrough stroke","Risk stratification","Atrial fibrillation","Anticoagulant therapy","Direct oral anticoagulant","2025-11-17",{"date":685,"type":40},"2025-11-20",{"date":687,"type":40},"2025-11-04",{"date":689,"type":21},"2028-06-30",{"name":691,"class":127},"Insel Gruppe AG, University Hospital Bern",{"id":693,"slug":4,"hasResults":11,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":4,"eligibilityCriteria":697,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":251,"enrollmentInfo":698,"targetDuration":4,"studyType":22,"phases":700,"briefSummary":701,"conditions":702,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":706,"lastUpdatePostDateStruct":707,"startDateStruct":709,"completionDateStruct":711,"leadSponsor":712,"locationsCount":152},"100597274","NCT07056361","Stimulating Specific Brain Areas (VOP\u002FVIM) With Electricity to Improve Movement and Muscle Control","VOP\u002FVIM Direct Electrical Stimulation Increases Motor Cortex Excitability and Motor Output","Inclusion Criteria:\n\n* Essential tremor patients who are scheduled to undergo deep brain stimulation surgery at UPMC Presbyterian with asymmetric essential tremor symptoms will be included, with the tested limb corresponding to the least affected arm to better approximate normal function. These patients are implanted bilaterally regardless of symptom laterality, as the natural history of essential tremor indicates eventual bilateral symptoms.\n* Parkinson's Disease patients who are scheduled to undergo deep brain stimulation surgery at UPMC Presbyterian with a history of Parkinson's Disease will also be recruited for intra-operative stimulation of their STN-targeted implants, to assess if VIM\u002FVOP has high specificity for improving motor output.\n\nConfirmation that subjects' terms of insurance coverage for their standard of care procedure will not be altered by study enrollment.\n\nExclusion Criteria:\n\n* Patients will be excluded from the study if there is any seizure history, to avoid the increased epileptogenic risk of intraoperative stimulation.\n* Patients with significant bilateral tremor that precludes completion of motor tasks.",{"count":699,"type":21},60,[138],"In this study the investigators aim to enroll patients scheduled to undergo deep brain stimulation (DBS) implantation for movement disorders for intra-operative testing. In addition to standard-of-care surgical procedure to implant deep brain stimulation electrode leads, participants will also be stimulated and recorded from cortical areas by a temporary strip electrode (1X6) in the subdural space. The electrodes will be connected to external stimulators and a series of experiments will be performed to assess effects of the DBS on movement quality and electrophysiology measures. Results of this study will elucidate the biological mechanisms related to deep brain stimulation in modulating motor and speech function in patients with abnormal movement disorders.",[703,141,704,34,466,705],"Movement Disorders (Incl Parkinsonism)","Traumatic Brain Injury","Essential Tremor, Movement Disorders","2025-11-05",{"date":708,"type":40},"2025-11-10",{"date":710,"type":40},"2022-12-16",{"date":601,"type":21},{"name":713,"class":127},"Jorge Gonzalez-Martinez",{"id":715,"slug":4,"hasResults":11,"nctId":716,"briefTitle":717,"officialTitle":718,"acronym":719,"eligibilityCriteria":720,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":721,"targetDuration":4,"studyType":22,"phases":723,"briefSummary":724,"conditions":725,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":728,"lastUpdatePostDateStruct":729,"startDateStruct":731,"completionDateStruct":733,"leadSponsor":734,"locationsCount":152},"100583103","NCT06871969","Clinical Evaluation of EEG Device for the Triage of Stroke Patients in the Ambulance","Clinical Evaluation of Pre-hospital Stroke Triage Devices - Electroencephalography","CROSSROADS-EEG","Inclusion Criteria:\n\n* Suspected acute stroke as per judgement of the ambulance personnel.\n* Age 18 years or older.\n* Onset of symptoms (or last seen well) \\\u003C24 hours.\n* Written informed consent by patient or legal representative (deferred).\n\nExclusion Criteria:\n\n\\- Injuries or infections of the scalp in the area of the electrode headset placement.",{"count":722,"type":21},275,[138],"Endovascular thrombectomy (EVT) is the standard treatment for large vessel occlusion (LVO) strokes, but it can only be performed in specialized hospitals. Since ambulance personnel cannot determine if a patient is eligible for EVT, 54% of LVO stroke patients are initially taken to non-EVT-capable hospitals, resulting in an average delay of 1 hour in time-to-EVT in the Netherlands. To reduce this delay, it is crucial for ambulance personnel to identify potential LVO stroke patients and directly transport them to EVT-capable hospitals. Dry electrode electroencephalography (EEG) has shown high diagnostic accuracy for detecting LVO strokes, but in 32% of patients, the EEG signal quality was too poor to analyze.\n\nTo address this issue, TrianecT developed StrokePointer, a portable EEG-based triage device designed to collect and analyze EEG data in patients with suspected acute stroke. The objective of this study is to validate the effectiveness and safety of StrokePointer in detecting LVO stroke among patients with a suspected stroke in the pre-hospital setting.",[226,141,726,143,35,34,84,727],"Cardiovascular Diseases","Cerebrovascular Disease","2025-09-30",{"date":730,"type":40},"2025-10-03",{"date":732,"type":40},"2025-07-01",{"date":44,"type":21},{"name":735,"class":127},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":737,"slug":4,"hasResults":11,"nctId":738,"briefTitle":739,"officialTitle":740,"acronym":4,"eligibilityCriteria":741,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":742,"targetDuration":4,"studyType":22,"phases":744,"briefSummary":745,"conditions":746,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":748,"lastUpdatePostDateStruct":749,"startDateStruct":751,"completionDateStruct":753,"leadSponsor":755,"locationsCount":152},"100579081","NCT06819657","Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping","Remote Ischemic Conditioning for Safety, Feasibility, and Preliminary Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping: An Open-Label, Evaluator-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n1. Imaging examination confirmed aneurysmal subarachnoid hemorrhage.\n2. Responsible aneurysms received craniotomy clipping within 24 hours.\n3. 18≤ age ≤80 years old.\n4. Informed consent of the participant or legally authorized representative\n\nExclusion Criteria:\n\n1. Patients with other types of cerebral hemorrhage.\n2. Prior neurological impairment (mRS Score \\>1) or mental illness may confuse neurological or functional assessment.\n3. Severe comorbidities with a life expectancy of less than 90 days.\n4. Refractory hypertension (systolic blood pressure 180\\>mmHg or diastolic blood pressure 110\\>mmHg).\n5. RIC contraindications: severe soft tissue injury of lower limbs.\n6. Simultaneously participate in another research program to study a different experimental therapy.\n7. Any condition that the investigator believes may increase the patient's risk.",{"count":743,"type":21},40,[138],"This study was designed to evaluate the safety and efficacy of remote ischemic conditioning (RIC) in patients with aneurysmal subarachnoid hemorrhage (aSAH) following surgical clipping.\n\nAneurysmal subarachnoid hemorrhage is a life-threatening condition that occurs when a cerebral aneurysm ruptures, causing bleeding into the subarachnoid space. Surgical clipping of the aneurysm is a standard procedure used to stop the bleeding and prevent re-rupture, thereby stabilizing the patient's condition.\n\nRemote ischemic conditioning (RIC) is a non-invasive treatment that involves using a blood pressure cuff to induce brief, temporary cycles of ischemia and reperfusion in a limb. Research suggests that this process may confer systemic protective effects, potentially improving recovery from brain injury or surgery. Although RIC has shown potential to improve outcomes in patients with other neurological conditions, its effect on patients with aSAH who undergo surgical clipping remains unclear.\n\nThis study will evaluate whether RIC can reduce complications, improve neurological function, and enhance overall recovery in these patients. The findings will help determine whether RIC should be incorporated into the standard treatment regimen for aSAH.",[747,142,34,141,726,143,84],"Subarachnoid Hemorrhage, Aneurysmal","2025-09-08",{"date":750,"type":40},"2025-09-09",{"date":752,"type":40},"2025-03-10",{"date":754,"type":21},"2026-03-30",{"name":756,"class":127},"Beijing Tiantan Hospital",""]